Mesoblast company profile

MSB · ASX · AUD

Compare Mesoblast
$1.70Change from previous close: −0.59%Absolute change: −$0.01

Close · November 20, 2026

Company profile

Mesoblast has 108 employees and is headquartered in Melbourne, Australia.

Melbourne-based Mesoblast has existed since 2004 and works on regenerative medicine products in Australia. Its platform relies on mesenchymal lineage cells, and the portfolio includes Ryoncil, aimed at graft versus host disease in children and at inflammatory bowel conditions, Revascor for hypoplastic left heart syndrome, and remestemcel-L, which is in Phase III trials for heart failure and degenerative back pain. The pipeline also includes MPC-300-IV for rheumatoid arthritis and MPC-25-IC for acute myocardial infarction. Partnerships with Tasly Pharmaceutical Group, Grünenthal GmbH and JCR Pharmaceuticals Co. Ltd. cover several of the candidates under development.

In the fiscal year ended June 2026, Mesoblast reported revenue of 120.3 million US dollars and a net loss of 57.5 million US dollars. The company employs 108 people at its headquarters in Melbourne, and the figures are stated in US dollars.

Company facts

Industry
Biotechnology
Country
Australia
Headquarters
55 Collins Street, 3000, Melbourne
Employees
108
Chief executive
Silviu Itescu
Founded
2004
Fiscal year
July - June
Listing
MSB · ASX
Currency
AUD
ISIN
AU000000MSB8

Mesoblast and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
MesoblastMSBAustralia$1.48B108-42.6%—
Neuren PharmaceuticalsNEUAustralia$1.83B819.9%144.0
Metis TechBio7666Hong Kong SAR China$1.11B150-131.2%—
InSilico Medicine Cayman TopCo3696Hong Kong SAR China$2.59B333-6.9%—
Telix PharmaceuticalsTLXAustralia$2.92B1,1206.2%92.3
3SBio1530Hong Kong SAR China$4.56B6,06860.3%3.90

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Mesoblast with its competitors